logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10519105 B1

PDFFull Text
Date of Patent:
Dec. 31, 2019

Filed:

Apr. 21, 2017

Kcnq2-5 channel activator

Applicant:

Ono Pharmaceutical Co., Ltd., Osaka-shi, Osaka, JP;

Inventors:

Kentaro Yashiro, Osaka, JP;

Masashi Kato, Osaka, JP;

Tetsuji Saito, Osaka, JP;

Takuya Okada, Osaka, JP;

Daisuke Wakamatsu, Osaka, JP;

Adam James Davenport, Abingdon, GB;

Christopher Charles Stimson, Abingdon, GB;

Assignee:

ONO PHARMACEUTICAL CO., LTD., Osaka-Shi, Osaka, JP;

Attorney:

Foley & Lardner LLP

Primary Examiner:

Po-Chih Chen

Int. Cl.
CPC ...
C07C 275/32 (2006.01); C07C 271/30 (2006.01); A61P 13/02 (2006.01); A61K 31/17 (2006.01); A61K 31/27 (2006.01); A61K 31/341 (2006.01); A61K 31/351 (2006.01); A61K 31/4045 (2006.01); A61K 31/42 (2006.01); A61K 31/426 (2006.01); A61K 31/44 (2006.01); A61K 31/4545 (2006.01); A61K 31/4965 (2006.01); A61K 31/505 (2006.01); C07D 213/74 (2006.01); C07D 309/04 (2006.01); C07D 239/26 (2006.01); C07D 241/12 (2006.01); C07D 261/08 (2006.01); C07D 277/28 (2006.01); C07D 209/14 (2006.01); C07D 213/40 (2006.01); C07D 213/64 (2006.01); C07D 307/52 (2006.01); A61P 13/10 (2006.01);
U.S. Cl.
CPC ...
C07C 275/32 (2013.01); A61K 31/17 (2013.01); A61K 31/27 (2013.01); A61K 31/341 (2013.01); A61K 31/351 (2013.01); A61K 31/4045 (2013.01); A61K 31/42 (2013.01); A61K 31/426 (2013.01); A61K 31/44 (2013.01); A61K 31/4545 (2013.01); A61K 31/4965 (2013.01); A61K 31/505 (2013.01); A61P 13/02 (2018.01); A61P 13/10 (2018.01); C07C 271/30 (2013.01); C07D 209/14 (2013.01); C07D 213/40 (2013.01); C07D 213/64 (2013.01); C07D 213/74 (2013.01); C07D 239/26 (2013.01); C07D 241/12 (2013.01); C07D 261/08 (2013.01); C07D 277/28 (2013.01); C07D 307/52 (2013.01); C07D 309/04 (2013.01); C07C 2602/08 (2017.05);
Abstract

An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (I) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (I) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).

Find Patent Forward Citations

Loading…